GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Compugen Ltd (XTAE:CGEN) » Definitions » Stock Based Compensation

Compugen (XTAE:CGEN) Stock Based Compensation : ₪0.0 Mil (TTM As of Dec. 2023)


View and export this data going back to 2002. Start your Free Trial

What is Compugen Stock Based Compensation?

Compugen's Stock Based Compensation for the three months ended in Dec. 2023 was ₪0.0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2023 was ₪0.0 Mil.


Compugen Stock Based Compensation Historical Data

The historical data trend for Compugen's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Compugen Stock Based Compensation Chart

Compugen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.93 10.26 15.86 16.04 13.15

Compugen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Compugen Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₪0.0 Mil.


Compugen Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Compugen's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


Compugen (XTAE:CGEN) Business Description

Traded in Other Exchanges
Address
26 Harokmim Street, Building D, Azrieli Center, Holon, ISR, 5885849
Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902, bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

Compugen (XTAE:CGEN) Headlines